• Title
  • InnovFin Infectious Diseases

  • Long Title

  • Banner Title
  •  

  • Id photos without linguistic version


  • Collection

  • Summary
  • The InnovFin Infectious Diseases Finance Facility (IDFF) provides financial products ranging from standard debt to equity-type financing for amounts typically between EUR 7.5 million and EUR 75 million, to innovative players active in developing innovative vaccines, drugs, medical and diagnostic devices or novel research infrastructures for combatting infectious diseases.


  • Article
  • InnovFin Infectious Diseases

    The InnovFin Infectious Diseases Finance Facility (IDFF) provides financial products ranging from standard debt to equity-type financing for amounts typically between EUR 7.5 million and EUR 75 million, to innovative players active in developing innovative vaccines, drugs, medical and diagnostic devices or novel research infrastructures for combatting infectious diseases.

    Project costs may include clinical trial costs, set-up of commercialisation such as market access, development of prototypes or industrial roll-out of novel equipment, pre-clinical R&D costs and working capital requirement.

    The product is being made available directly through the European Investment Bank.

    Eligibility

    To be eligible for InnovFin Infectious Diseases Finance Facility (IDFF) funding, counterparties must comply with the following criteria:

    The promoter should be a large pharmaceutical company, a mid-cap or a small and medium-sized enterprise (SME), a research institute/organisation, a university, a non-profit entity or a special-purpose vehicle (SPV). Promoters, sponsors and/or operators must be willing to substantially co-fund the project.

    Geography

    The beneficiary must be established and operating in one or several of the Member States and Horizon 2020 Associated Countries. The project and/or the intellectual property (IP) development (e.g. clinical trials) can be undertaken outside Member States and Horizon 2020 Associated Countries.

    Innovativeness

    The project must have a proven public health impact and potential market prospects.

    Funding from the IDFF must be invested in developing and producing innovative products, processes and/or services in the field of infectious diseases.

    Validated technology

    Projects must relate to pre-commercial stage investments in the field of infectious diseases (ID), i.e. the project must develop and produce innovative vaccines, drugs, medical and diagnostic devices, and infrastructure in the field of ID.

    The product should have passed successfully through the pre-clinical stage or through the proof-of-concept stage (in the case of medical and diagnostic devices).

    Funding can be invested in research infrastructure that provides facilities, resources and related services for use by the scientific community to conduct top-level research in the ID field.

    Commitment

    The operations to be financed will be selected by the EIB, taking also into account aspects such as the operation’s risk profile and bankability prospects, the overall IDFF funding available, portfolio composition and other transactions in the pipeline.

    How to apply

    Find out on this page how you can benefit from the InnovFin Infectious Diseases Finance Facility.


  • Central Box
  • Alternate title
  • 3 new ways to treat cancer
  • Alternate summary
  • Companies developing new cancer treatments have a hard time raising the money to carry out their research, so the European Investment Bank finances them.

  • ID photo
  • 9250bc83-d101-4b4c-aea6-8d038762284a

  • Related page title
  • Molecular diagnostics save lives and money
  • Related page summary
  • Three European start-ups are developing automated molecular diagnostics tests that slash the time it takes to detect and treat serious gastro-intestinal and respiratory diseases for patients admitted in emergency departments and intensive care units.

  • ID photo

  • Sub Article

  • Right column

  • Related Documents

  • Last modified-on: 03-06-2020